KRAS and familial pancreatic carcinoma: In pancreatic cancer, an open-label, phase 2 RCT comparing stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib versus SBRT plus gemcitabine for locally recurrent pancreatic cancer post-operation reported that patients with KRAS mutations as well as high PD-L1 expression had a median OS of 14.9 and 12.8 months, respectively, with the major AEs being increased blood bilirubin and liver impairment [87].